# Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC

> **NCT00356941** · PHASE1 · TERMINATED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 4 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** oxaliplatin
- **PROCEDURE:** radiation therapy

## Key facts

- **NCT ID:** NCT00356941
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-04
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Withdrawn due to lack of accrual
- **Last updated:** 2017-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00356941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00356941, "Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00356941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*